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clinical communities, for up-to-date data on matching and trans-
plant outcome. Only data with the explicit consent of the partici-
pating center have been entered into this database. All data have
been stripped of personal identiﬁers and links to submitting centers
in order to protect patient anonymity. All centers contributing to
this resource are listed on the main page of this project. Currently
updates of the data contained at this site are submitted via the
IHWG database. The HCT database currently contains data on
1551 unrelated donor transplants from 24 centers in 15 countries.
Data cover high resolution HLA typing for patient and donor of
HLA-A, B, C, DRB, DQB, DPB, diagnosis and stage at transplant,
patient and donor age and gender, survival and relapse. Transplant
pairs can be analyzed as deﬁned by the user. Data can be sorted,
viewed and downloaded by HLA allele or allele groups (i.e., HLA-
A*02), level of mismatch, and diagnosis. A special tool allows users
to interactively calculate, display, and download Kaplan Meier
Survival estimates for each user-deﬁned group of transplant pairs.
Download options of the data are available as individual data sets of
donor recipient pairs, as calculated data representing the outcome
of the Kaplan Meier estimate, or as images of Kaplan Meier
Curves. The database has been designed to include additional
genotyping data, e.g. KIR typing, SNPs, or microsatellites for each
donor-recipient pair. As data on additional genes becomes avail-
able, the database will be expanded to allow queries for combina-
tions of different genetic loci.
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THE IMPACT OF AGE AND OBESITY ON PLASMA BUSULFAN LEVELS
Im, E.K.; Cronin, S.; Levine, J.E.; Braun, T.; Yanik, G.; Reynolds, C.;
Uberti, J.P.; Ferrara, J.L.; Hutchinson, R.J. University of Michigan
Blood and Marrow Transplantation Program, Ann Arbor, MI.
IV busulfan is an alternative to oral busulfan in myeloablative
regimens prior to hematopoietic stem cell transplantation
(HSCT). Compared to oral busulfan which has variable bioavail-
ability, IV busulfan assures consistent drug delivery and may be
associated with a lower incidence of regimen-related toxicity. We
were interested in the effect of the type of body weight calculation
used for dosing busulfan on plasma busulfan levels. We investi-
gated the pharmacokinetic data from 58 sequential patients (age
7 m to 67 y) who received IV busulfan. In addition, the pharma-
cokinetic data for 11 patients who were obese or under weight who
received oral busulfan during the study period were also reviewed.
Patients received IV busulfan (0.8 mg/kg), or oral busulfan (1
mg/kg). Patients whose actual weight exceeded 140% of their ideal
body weight were dosed according to ideal [n12] or adjusted
[n29] body weight. The target Css range for all patients was
600–900 ng/ml. Plasma busulfan Css was measured at a single
reference laboratory by gas chromatography and mass spectrome-
try. Based on the pharmacokinetic result, remaining busulfan doses
were adjusted to achieve the desired Css target when averaged over
the 4-day dosing period. There was a signiﬁcant difference in mean
Css values between the IV and oral busulfan groups (727 ng/ml vs
986 ng/ml respectively) (p
0.001); furthermore there was less
variability in the Css for the IV group compared to the oral group
(p0.01). When IV busulfan patients were analyzed, a signiﬁcant
difference was observed among mean Css values of the actual,
ideal, and adjusted ideal body weight groups (658 ng/ml, 707
ng/ml, and 797 ng/ml) (p0.01). Consistent with other studies, we
found an inverse association between the age and busulfan clear-
ance in IV busulfan group (p0.004). In addition, 6/9 patients
between the age of 1 to 10 years had Css below the minimum
target. In this study, patients from 1 to 10 were all dosed by actual
body weight. In conclusion, use of IV busulfan produces a nar-
rower range of Css values. Both age and the choice of body weight
calculation for dosing impacts plasma busulfan levels. Consider-
ation should be given to increase dosing for children
10 years old.
Both adjusted and ideal body weight calculations led to Css values
in the target range. The use of ideal rather than adjusted ideal body
weight for dosing obese patients yielded Css values similar to that
achieved when using actual body weight for non-obese patients.
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BONE MARROW TRANSPLANTATION FOR DYSKERATOSIS CONGENITA:
ANALYSIS OF COMPLICATIONS AND LONG TERM FOLLOW-UP
Bonﬁm, C.M.S.; Bitencourt, M.A.; Funke, V.A.; Setubal, D.C.; Ruiz,
J.; Zanis-Neto, J.; deMedeiros, C.R.; Silva, R.L.F.; Pasquini, R. Bone
Marrow Transplantation Service Hospital de Clinicas UFPR, Curitiba,
PR, Brazil.
Introduction: DC is a rare bone marrow failure syndrome as-
sociated with aplastic anemia in approximately 50% of the cases.
It’s usually inherited in a X-linked manner and the diagnostic triad
includes reticulate hyper pigmentation, nail dystrophy and mucous
leukoplasia. Bone marrow transplantation (BMT) remains the only
potential curative treatment for these pts. Material and Methods:
Between 07/1993 and 07/2001, 5 pts with DC received an HLA
identical sibling BMT in our service. Sex M/F: 4/1. Median age at
BMT: 17 y (8–21).Median previous blood transfusions: 25 UI
(6–50 UI). All but one presented with nail dystrophy, abnormal
skin pigmentation and oral leukoplasia and had severe pancytope-
nia. Preparative regimen: Cyclophosphamide 200 mg/kg. GVHD
prophylaxis: Cyclosporine (csa)  methotrexate. Stem cell source:
bone marrow. TNC infused ranged from 2.2–5.13  108/kg (M:
2.27). Prophylactic antibiotics were given according to common
practice. Results: All pts are alive with a median follow up of 6
years (range: 3.2–11.2 y) and have full donor engraftment. Median
time to reach neutrophils 500/l was 27 days and platelets
20,000/l was 26 days after transplant. Two pts have a lower
platelet count (80,000/l) without any symptoms. Mucositis grade
II occurred in most pts. No pt developed acute or chronic GVHD,
VOD or autoimmune complications. Four pts developed eye com-
plications and two of them had to be submitted to eye surgery
(posterior uveitis and cornea transplantation for bilateral kerato-
conus). Only one pt complained of dry cough and progressive
dyspnea 10 years after transplant. He was evaluated at our BMT
Unit in 07/2004 when he presented with severe dyspnea and
hypoxemia (pO2: 61 mmHg). The chest CT showed diffuse inter-
stitial lesions and spirometry revealed a severe restrictive defect.
Echocardiogram was normal without pulmonary hypertension.
Pulmonary biopsy showed interstitial pulmonary ﬁbrosis with focal
areas of lymphocyte inﬁltrates. He was treated with steroids in
08/2004 and despite the very short follow up there is evidence of
clinical improvement (less fatigue and dyspnea and pO2: 89
mmHg). Conclusions: This preparatory regimen is safe and ef-
fective for the correction of the hematopoietic failure in pts with
DC, followed by a low complication rate. The mucocutaneous
abnormalities remain unchanged. Late pulmonary complications
occurred despite the absence of TBI in the preparative regimen.
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NK CELL ALLOREACTIVITY IS AN IMPORTANT MEDIATOR OF COSTIMU-
LATION-BLOCKADE-RESISTANT REJECTION DURING ALLOGENEIC
TRANSPLANTATION
Kean, L.S.1; Hamby, K.2; Coley, S.2; Lee, E.2; Adams, A.2; Pearson, T.2;
Larsen, C.2 1. Division of Hematology/Oncology/BMT, Department of
Pediatrics, and Department of Surgery, Atlanta, GA; 2. Department of
Surgery, Atlanta, GA.
Introduction: Immunologic tolerance remains an elusive goal of
clinical transplantation. Work in murine systems has demonstrated
that T-cell tolerance can be accomplished by providing T cells
with “signal 1” (alloantigen) while blocking “signal 2” through
costimulation blockade. We have used the costimulation blockade
reagents CTLA4-Ig and anti-CD40L in conjunction with nonmy-
eloablative bone marrow transplant to produce transplantation
tolerance in a fully MHC-mismatched murine system. However,
relatively large bone marrow doses (10  109/kg) must be used.
Costimulation-blockade-resistant rejection occurs when smaller
cell doses are transplanted. In this study, we investigated the
contribution of NK cell alloreactivity to this costimulation-block-
ade-resistant rejection response. Methods: We transplanted in-
creasing doses of Balb/C (NK1.1) bone marrow (0.5-, 2-, 5-, 10-,
and 20  106 cells) into C57BL/6 (NK1.1) mice after treatment
with 20 mg/kg busulfan. Costimulation-blockade with CTLA4-Ig
and anti-CD40L was given in the peritransplant period. Three
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